gefitinib (Iressa)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradname: Iressa (FDA approved 2003)

Indications

* NSCLC with EGFR mutation (exon 19 deletions or exon 21 L858R substitution gene mutations)[3]

* ~10% of tumors shrink in size

* NOT recemmended (NICE) [NGC]

Dosage

oral agent

Adverse effects

Laboratory

Mechanism of action

More general terms

References

  1. Prescriber's Letter 10(6):35 2003
  2. Jump up to: 2.0 2.1 2.2 Medical Knowledge Self Assessment Program (MKSAP) 16, American College of Physicians, Philadelphia 2012
  3. Jump up to: 3.0 3.1 3.2 3.3 FDA News Release. July 13, 2015 FDA approves targeted therapy for first-line treatment of patients with a type of metastatic lung cancer http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm454678.htm

Database